---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-396690"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2026-09-21T20:20:00+00:00"
generated_at: "2026-09-21T20:21:18.184353+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio reports FY2026 net income $176.4M; Jemperli sales up 34% YoY

## Summary
- Jemperli global net sales $644M (£480M) for six months ended Jun 30, 2026, +34% YoY; Q2 $331M, +26% YoY.
- FDA PDUFA Feb 2027 for Jemperli in dMMR/MSI-H rectal cancer; AZUR-1 interim results met primary cCR12 endpoint.
- GSK/Tesaro litigation: trial held Jul 14-17; post-trial hearing Oct 20; judgement expected Q4 2026/Q1 2027, seeking Jemperli reversion.
- Cash $164.1M at Jun 30, 2026 vs $211.6M at Dec 31, 2025; collaboration revenue $53.0M for six months.
- Net income from continuing ops $176.4M ($6.09 diluted EPS) for six months; $181.5M tax benefit from valuation allowance release.

## SEC filing metadata
- accession: 0001193125-26-396690
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2026-09-21T20:20:00+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000119312526396690/0001193125-26-396690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000119312526396690/anab-20260921.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-396690
- JSON: https://secwatch.observer/filing/0001193125-26-396690.json
- Plain text: https://secwatch.observer/filing/0001193125-26-396690.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.